Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 238

The DOI matches its Crossref record.

Osteonecrosis of the Jaw Related to Bevacizumab

Open access
Estilo, Cherry L., Fornier, Monica, Farooki, Azeez, Carlson, Diane, Bohle, George, Huryn, Joseph M. · 2008 · Journal of Clinical Oncology

Abstract

Osteonecrosis of the Jaw Related to BevacizumabA 51-year-old female with history of infiltrating ductal carcinoma of the right breast was diagnosed in late 2001 and treated with mastectomy in February 2002.She was subsequently treated with adjuvant chemotherapy with doxorubicin and cyclophosphamide for four cycles followed by hormonal therapy with letrozole for three years.She was diagnosed with a chest wall recurrence, involving the soft tissues in the right axillary and supra-clavicular areas in early 2006 and underwent six cycles of chemotherapy with albumin-bound nanoparticle-paclitaxel.She subsequently underwent a chest wall resection in September 2006, followed by radiation to the chest wall.She started capecitabine at the dose of 1000 mg twice a day, two weeks on and one week off, in October 2006 (in concurrence with radiation therapy to the chest wall).In December 2006, the dose of capecitabine was increased to 1500 mg AM and 1000 mg PM, also two weeks on and one week off.Bevacizumab was also started in late December 2006 at the dose of 15 mg/kg for 3 weeks for a total of 8 doses, the last one in May 2007.Six weeks following the last dose of bevacizumab, the patient presented with a 2-month history of complaints of lower jaw discomfort and what the she described as protruding bone in the lower jaw.The patient denied any recent history of dental or oral surgery.Examination revealed a small area of bone exposure in the left posterior lingual mandible, measuring approximately 1 ϫ 1 mm in diameter.The bone appeared necrotic.The surrounding soft tissue appeared normal with no evidence of infection.The rest of the oral and dental examination was unremarkable.The exposed bone was smoothed with a bone file.The patient was prescribed chlorhexidine 0.12% oral rinse.Bevacizumab and capecitabine were discontinued.A few weeks later, the area of exposed bone had resolved.The overlying mucosa appeared normal.However, there was now a new area of 1 ϫ 1 mm exposed bone in the right posterior lingual mandible (Fig 1A).The bone was mobile and was easily removed.Histological examination of the bony specimen (Fig 1B) showed devitalized, necrotic bone (NB, black arrowhead) demonstrating a scalloped, "moth-eaten" appearance.Bacterial colonies occupied those areas in which there was loss of mineralized bone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.15.5424

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 238

Metadata

Authors
Estilo, C. L., Fornier, M., Farooki, A., Carlson, D., Bohle, G., & Huryn, J. M.
Venue
Journal of Clinical Oncology
Published
2008-08-20
Volume
26
Issue
24
Pages
4037-4038
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2122429800
Cited by
238
References
0
FWCI
9.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Osteonecrosis of the Jaw Related to Bevacizumab. https://app.cochat.ai/papers/10.1200/jco.2007.15.5424
The paper
Estilo, C. L., Fornier, M., Farooki, A., Carlson, D., Bohle, G., & Huryn, J. M. (2008). Osteonecrosis of the Jaw Related to Bevacizumab. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.5424

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.